Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo

International Journal of Cancer

Volumn 136, Issue 2, 2015, Pages 462-475

  Mezouar, Soraya ^a   Darbousset, Roxane ^a   Dignat George, Françoise ^a,b   Panicot Dubois, Laurence ^a   Dubois, Christophe ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

Author keywords

microparticles; pancreatic cancer; platelets; thrombosis; tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; ALPHAVBETA1 INTEGRIN; CLOPIDOGREL; FIBRIN; FIBRINOGEN; INTEGRIN; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANTITHROMBOCYTIC AGENT; MESSENGER RNA; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BLEEDING TIME; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CELL INTERACTION; CONTROLLED STUDY; HEMOSTASIS; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; C57BL MOUSE; COMPLICATION; DISEASE MODEL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MEMBRANE MICROPARTICLE; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BLOOD COAGULATION; BLOTTING, WESTERN; CELL-DERIVED MICROPARTICLES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; INTEGRINS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; P-SELECTIN; PANCREATIC NEOPLASMS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOPLASTIN; THROMBOSIS; TICLOPIDINE; TUMOR CELLS, CULTURED;

EID: 84922323122     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28997     Document Type: Article

References (40)

1. Sack GH Jr, Levin J, Bell WR,. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56: 1-37.
2. Blom JW, Vanderschoot JPM, Oostindiër MJ, et al., Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost JTH 2006; 4: 529-35.
3. White RH, Chew HK, Zhou H, et al., Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165: 1782-7.
4. Alcalay A, Wun T, Khatri V, et al., Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol Off J Am Soc Clin Oncol. 2006; 24: 1112-8.
5. Guzmán-Uribe P, Rosas-Lõpez A, Zepeda-Leõn J, et al., Incidence of thrombosis in adults with acute leukemia: a single center experience in Mexico. Rev Investig Clínica Organo Hosp Enfermedades Nutr 2013; 65: 130-40.
6. Neoptolemos JP, Stocken DD, Dunn JA, et al., Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758-68.
7. Walker G, Xenophontos M, Chen L, et al., Long-term efficacy and safety of exemestane in the treatment of breast cancer. Patient Prefer Adherence 2013; 7: 245-58.
8. Sørensen HT, Mellemkjaer L, Olsen JH, et al., Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343: 1846-50.
9. Gasic GJ, Koch PA, Hsu B, et al., Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastases. Z Für Krebsforsch Klin Onkol Cancer Res Clin Oncol 1976; 86: 263-77.
10. Sierko E, Wojtukiewicz MZ,. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost 2007; 33: 712-21.
11. Schaffner F, Ruf W,. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol 2009; 29: 1999-2004.
12. Winter PC,. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol 2006; 24: 126-33.
13. Thomas GM, Panicot-Dubois L, Lacroix R, et al., Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206: 1913-27.
14. Atkinson BT, Jasuja R, Chen VM, et al., Laser-induced endothelial cell activation supports fibrin formation. Blood 2010; 116: 4675-83.
15. Corbett TH, Roberts BJ, Leopold WR, et al., Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984; 44: 717-26.
16. Panicot-Dubois L, Thomas GM, Furie BC, et al., Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans. J Clin Invest 2007; 117: 3708-19.
17. Hubert L, Darbousset R, Panicot-Dubois L, Robert S, Sabatier F, Fallague K, et al., Neutrophils recruit and activate Human Endothelial Colony Forming Cells at the site of vessel injury via PSGL-1 and L-Selectin. J Thromb Haemost 2014 Mar 8; DOI: 10.1111/jth.12551.
18. Kim MP, Evans DB, Wang H, et al., Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009; 4: 1670-80.
19. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, et al., Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006; 107: 3902-6.
20. Dubois C, Panicot-Dubois L, Gainor JF, et al., Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 2007; 117: 953-60.
21. Yu JL, May L, Lhotak V, et al., Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734-41.
22. De Oliveira ADS, Lima LG, Mariano-Oliveira A, et al., Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma. Thromb Res 2012; 130: e163-170.
23. Darbousset R, Thomas MG, Mezouar S, et al., Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 2012; 120: 2133-43.
24. Falati S, Liu Q, Gross P, et al., Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98.
25. Sitia G, Aiolfi R, Di Lucia P, et al., Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012; 109: E2165-72.
26. Chiodoni C, Iezzi M, Guiducci C, et al., Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 2006; 203: 2441-50.
27. Ruf W, Yokota N, Schaffner F,. Tissue factor in cancer progression and angiogenesis. Thromb Res 2010; 125: S36-38.
28. Ott I, Fischer EG, Miyagi Y, et al., A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140: 1241-53.
29. Zucker S, Mirza H, Conner CE, et al., Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998; 75: 780-6.
30. Carney DH, Herbosa GJ, Stiernberg J, et al., Double-signal hypothesis for thrombin initiation of cell proliferation. Semin Thromb Hemost 1986; 12: 231-40.
31. Darmoul D, Gratio V, Devaud H, et al., Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003; 162: 1503-13.
32. Camez A, Dupuy E, Bellucci S, et al., Human platelet-tumor cell interactions vary with the tumor cell lines. Invasion Metastasis 1986; 6: 321-34.
33. Jurasz P, Sawicki G, Duszyk M, et al., Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 2001; 61: 376-82.
34. Alonso-Escolano D, Strongin AY, Chung AW, et al., Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol 2004; 141: 241-52.
35. Matsui Y, Amano H, Ito Y, et al., Thromboxane A2 receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells. Cancer Sci 2012; 103: 700-7.
36. Maugeri N, Di Fabio G, Barbanti M, et al., Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost 2007; 97: 965-73.
37. Rothwell PM, Price JF, Fowkes FG, et al., Short-term effects of daily Aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-12.
38. Rothwell PM, Wilson M, Price JF, et al., Effect of daily Aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601.
39. Stürmer T, Glynn RJ, Lee IM, et al., Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128: 713-20.
40. Cook NR, Lee I-M, Gaziano JM, et al., Low-dose Aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA J Am Med Assoc 2005; 294: 47-55.